Inventiva S.A. (Nasdaq: IVA), a pharmaceutical company, has announced encouraging results from a Phase II clinical trial evaluating lanifibranor in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2D). 

The study successfully achieved its primary efficacy endpoint, demonstrating a significant 44% reduction in intrahepatic triglycerides (IHTG) in patients treated with lanifibranor compared to a 12% reduction in the placebo group. 

Furthermore, lanifibranor exhibited positive outcomes in multiple secondary metabolic endpoints, affirming its cardiometabolic benefits and improvement in adipose tissue function. The trial also confirmed the drug's favorable safety and tolerability profile. 

Following this news, $IVA surged by 35.96% in after-hours, currently trading at $4.99.

89bio, Inc. (Nasdaq: ETNB), a biopharmaceutical company focused on developing innovative therapies, has been initiated with an Outperform rating and a price target of $49 at Evercore ISI.

Considering that $ETNB closed at $22.03 on Tuesday, this price target suggests a potential upside of $26.97 or 122.43%, based on Evercore ISI's analysis.

BRP Inc. (Nasdaq: DOOO), a leading global manufacturer of powersports vehicles and propulsion systems, has received an upgrade from Neutral to Buy at DA Davidson, accompanied by a price target increase from $111 to $126.

Given that $DOOO closed at $79.26 on Tuesday, this revised price target implies a potential upside of $46.74 or 58.95%, according to DA Davidson's assessment.

CompoSecure, Inc. (Nasdaq: CMPO), a provider of secure payment card solutions, has been initiated with a Buy rating and a price target of $13 at Berenberg.

Based on Tuesday's closing price of $7.05, this price target suggests a potential upside of $5.95 or 84.40% for $CMPO, as per Berenberg's analysis.

These potential upsides are based on the brokerage firms' or analysts' views and should be taken into consideration when evaluating investment decisions. The actual potential upsides may vary, and investors should conduct their own research and analysis before making any investment decisions.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)